Navigation Links
A Balanced Risk-Benefit Profile Will Propel Orexigen/Takeda's Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
Date:11/6/2013

BURLINGTON, Mass., Nov. 6, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that novel emerging agents will experience steady uptake owing to the high prevalence of obese or overweight individuals and the current lack of efficacious, safe and well-tolerated weight-loss drugs. However, none of the emerging therapies are set to dominate the space owing to historical safety concerns that have fostered a cautious attitude among physicians and regulatory authorities, particularly in markets outside the United States.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Obesity finds that Orexigen/Takeda's Contrave will become the most widely used emerging therapy due to the fact it offers the best available balance of efficacy and safety among the competing therapeutic entities. A 3.0 mg formulation of Novo Nordisk's Victoza will become the sales leader over the 2012-2022 forecast period, owing to its premium price combined with physician familiarity and the additional metabolic benefits the drug provides. The U.S. launches of Vivus's Qsymia and Arena Pharmaceuticals/Eisai's Belviq in 2012 and 2013, respectively, have both been met with modest uptake, suggesting that historical safety issues associated with antiobesity agents still weigh on the minds of physicians. European and Japanese physicians will also have new treatments available from early in the forecast period, although they will continue to have fewer options from which to choose than their U.S. counterparts.

Decision Resources forecasts that the obesity drug market will grow more than fivefold over the next decade to exceed $2.5 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan; market growth in the United States will be the predominant driver, overall. Novel agents that are forecast to launch over the next decade are expected to capture 91 percent of the obesity market in 2022. Increasing recognition of the medical importance of obesity and the high prevalence of the disease will drive continued demand for safe, efficacious and well tolerated weight-loss therapies.

"There is a great unmet need in the obesity market for agents that can induce satisfactory weight loss; a safe and well tolerated treatment filling the void between the efficacy offered by surgery and that offered by diet, exercise and behavioral modifications has not yet emerged," said Decision Resources Analyst Dr. Tim Blackstock, M.B. Ch.B.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
2. Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes
3. Emerging Drug Delivery Technologies, Profiles of Start-ups and Early-Stage Companies
4. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
5. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
6. Apama Medical Announces Issuance Of Patent For Low Profile Electrodes For Use On Balloons
7. CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
8. Bioabsorbable Stents - Global Strategic Business Report - 2013 Profiles 16 Companies inside the Market
9. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
10. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
11. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):